Wegovy vs Mounjaro: Different Molecules, Different Indications — How to Choose (2026)

Wegovy vs Mounjaro is the most-asked cross-class GLP-1 comparison — and one of the most confusing. Unlike Wegovy vs Ozempic (same molecule, different indication) or Mounjaro vs Zepbound (same molecule, different indication), Wegovy and Mounjaro contain different active ingredients (semaglutide vs tirzepatide) made by different manufacturers (Novo Nordisk vs Eli Lilly), each FDA-approved for a different indication (chronic weight management vs type 2 diabetes). Picking between them is actually picking between two clinical scenarios.

The short answer

If you have type 2 diabetes, your prescriber writes Mounjaro. If you have obesity (BMI ≥ 30) or overweight (BMI ≥ 27 with a weight-related comorbidity) but NOT type 2 diabetes, your prescriber writes Wegovy. The FDA-approved indication determines which brand a payer will cover. Off-label use of Mounjaro for weight loss in non-diabetics is legal but rarely insurance-covered.

For a fair efficacy comparison for weight loss, the right pair to compare is Wegovy vs Zepbound (both weight-management-indicated; SURMOUNT-5 NEJM 2025 showed tirzepatide ahead of semaglutide head-to-head). The Wegovy vs Mounjaro framing usually reflects the patient researching both because they appear in the same Google searches — not because they're the right side-by-side.

Side-by-side comparison

Decision: which one is your prescriber writing?

• If you have type 2 diabetes (with or without obesity): the conversation is Mounjaro (or its weight-loss-indicated twin Zepbound ). Both Cigna CNF 360 and Aetna 5468-C gate Mounjaro behind a metformin step-therapy requirement (eGFR <30 or established CVD as bypass routes). For verbatim payer policy language, see our Cigna PA guide and Aetna PA guide .
• If you have obesity or overweight + comorbidity but NOT type 2 diabetes: the conversation is Wegovy (or Zepbound — see the next bullet for which one is stronger). Both Cigna IP0206 and Aetna 4774-C cover Wegovy for chronic weight management with BMI requirements + a 3- or 6-month documented behavioral and dietary modification trial. Cigna's 11-condition comorbidity list and Aetna's comprehensive-program documentation are the two clauses that most prescribers under-document.
• If your goal is the largest possible weight loss and you don't have type 2 diabetes: the more informative comparison is Wegovy vs Zepbound, not Wegovy vs Mounjaro. SURMOUNT-5 (NEJM 2025) showed tirzepatide produces greater mean weight loss than semaglutide in a head-to-head. Zepbound is tirzepatide for chronic weight management — the same molecule as Mounjaro but the weight-management brand. See our brand-name cheat sheet for the side-by-side.
• If you have BOTH type 2 diabetes AND obesity: your prescriber may choose based on which indication your insurance covers most cleanly. Some patients run a year on Mounjaro for diabetes (with weight loss as a side benefit) and never need to escalate to Zepbound. Others have one indication covered and the other denied, which forces the decision.

Cost comparison

The cash-pay landscape for these two is asymmetric. Wegovy has Novo Nordisk's NovoCare DTC self-pay path at $299/mo for the standard pen (verified 2026-05-09). Mounjaro has NO direct manufacturer self-pay path — only the Mounjaro Savings Card for commercially insured patients with a diabetes diagnosis. Without commercial insurance + diabetes coverage, Mounjaro retail is ~$995/mo at the cheapest pharmacy via GoodRx.

• Wegovy NovoCare self-pay: $299/month (standard pen, all doses 0.25–2.4 mg)
• Wegovy oral pill 1.5/4 mg: $149/month (through Aug 31, 2026)
• Wegovy Costco CMPP via Sesame: $349/month
• Wegovy with insurance copay savings card: as little as $25/month
• Mounjaro retail (no DTC discount): ~$995/month at GoodRx cheapest pharmacy
• Mounjaro Savings Card (commercial insurance with diabetes coverage): as little as $25/month

For the full channel-by-channel cash-pay coupon guide across every GLP-1, see our GLP-1 cash-pay coupon & channel guide .

The off-label question

Patients sometimes ask whether they should ask their prescriber for Mounjaro instead of Wegovy because of a perception that Mounjaro is “stronger.” A few things to know:

• The molecule is what matters. Tirzepatide (the active ingredient in Mounjaro) is the same molecule as tirzepatide in Zepbound. If your goal is a tirzepatide prescription for weight loss, Zepbound is the weight-management brand and the path your prescriber + your insurance will accept.
• Off-label Mounjaro for weight loss is legal but rarely insurance-covered. Both Cigna and Aetna gate Mounjaro behind a documented type 2 diabetes diagnosis per CNF 360 + 5468-C respectively.
• Cash-pay Mounjaro is more expensive than cash-pay Zepbound. LillyDirect Self Pay Journey Program for Zepbound vials runs $299–$449/month; Mounjaro has no equivalent path.
• If you genuinely have both T2D and obesity, talk to your prescriber. The clinical decision depends on which indication is cleaner for your insurance and which dose tier fits your individual response.

For the Mounjaro-anchored alternatives map (when to switch Mounjaro→Zepbound for the same molecule, when to switch to a different T2D GLP-1, when to pivot to a weight-management drug because the off-label use is no longer covered), see Mounjaro alternatives — T2D-specifically .

What about other GLP-1s? (Trulicity, Ozempic, Saxenda, Foundayo)

The Wegovy vs Mounjaro framing covers the two most-prescribed molecules, but the GLP-1 class is broader. The other major agents and where they fit:

• Ozempic (semaglutide) — same molecule as Wegovy, FDA-approved for type 2 diabetes only. The T2D twin of Wegovy.
• Trulicity (dulaglutide) — the older once-weekly GLP-1 from Eli Lilly. FDA-approved for T2D and for MACE reduction in T2D + CV risk patients (REWIND, PMID 31189511 — 12% MACE reduction). NOT FDA-approved for chronic weight management. Off-label weight loss is meaningfully smaller than Wegovy or Zepbound (-4.6 kg at 4.5 mg max dose at 36 weeks per AWARD-11, PMID 33397768). Insurance coverage on T2D formularies is much broader than weight-management formularies, so for T2D patients Trulicity is often easier to get approved than Wegovy or Zepbound. See our Trulicity (dulaglutide) for weight loss evidence guide for the full off-label evidence base, dosing schedule, and BLA-biologic regulatory framing.
• Saxenda (liraglutide 3 mg) — daily injection, FDA-approved for chronic weight management. Older mechanism, smaller effect size (~8% at 56 weeks per SCALE Obesity, PMID 26132939). Generic available as of Aug 27, 2025 (Teva ANDA, the first FDA-approved generic GLP-1 RA for chronic weight management). For the verbatim FDA label, the SCALE pivotal-trial evidence, the adolescent indication, the Aetna 1227-C 4% continuation rule (NOT 5%), and the patient profiles for whom Saxenda still makes sense in 2026, see our Saxenda (liraglutide) FDA label, SCALE evidence, and Teva generic deep-dive .
• Foundayo (orforglipron) — daily oral tablet, FDA-approved April 2026 for chronic weight management. The first oral non-peptide GLP-1; effect size falls between Saxenda and Wegovy.
• Rybelsus (oral semaglutide) — daily oral tablet, FDA-approved for T2D only.
• Victoza (liraglutide) — daily injection, FDA-approved for T2D only. Generic available as of Dec 2024.

For the FAQ-style disambiguation hub answering all 21 patient-language same-as / class-membership / brand-vs-generic questions across this entire GLP-1 cluster (with FAQPage rich snippet schema), see our GLP-1 disambiguation FAQ hub .

Verification log

Every clinical claim above was verified against the verbatim Wegovy and Mounjaro DailyMed FDA labels on 2026-05-09. PMID citations (STEP-1 33567185, SURPASS-2 34170647, SURMOUNT-5 40353578) confirmed by direct PubMed fetch. Pricing data verified from primary-source channel pages on 2026-05-09 (see the channel guide cited above for source URLs).

Further reading

• Top tirzepatide weight-loss studies (curated PubMed reading list)
• Top tirzepatide questions on Reddit, answered
• Top semaglutide weight-loss studies (curated PubMed reading list)